Inactive Instrument

Christian Hansen

CHR

DK0060227585

Chr. Hansen Holding A/S Provides Earnings Guidance for the Year 2022

April 06, 2022 at 02:00 am EDT

Chr. Hansen Holding A/S provided earnings guidance for the year 2022. For the year, the company expects organic revenue growth in the range of 7%-11% (previously 5%-8%).

Latest news about Christian Hansen

Novozymes, Chr. Hansen Complete Merger Settlement	Feb. 02	MT
Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Nordic All-Share Index	Feb. 01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from FTSE All-World Index	Feb. 01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350 - Materials	Feb. 01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350	Feb. 01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350 - Materials (Industry Group)	Feb. 01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P International 700	Feb. 01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P Global 1200	Feb. 01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P Global BMI Index	Feb. 01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Copenhagen 20 Index	Jan. 30	CI
Novozymes Completes Merger with Chr. Hansen After Securing Final Registration, Issuing B Shares	Jan. 29	MT
Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S.	Jan. 28	CI
Novozymes, Chr. Hansen’s Proposed Merger Secures All Regulatory Approvals	Jan. 26	MT
Nordic Stocks Decreased Wednesday; Kone B Posted Biggest Loss	Jan. 17	DJ
Novozymes, Chr. Hansen Merger Wins Korean Regulatory Nod	Dec. 20	MT
Novozymes-Chr. Hansen Merger Gets EU Nod After Proposed Asset Sale	Dec. 12	MT
Kerry Group Buys Novozymes, Chr. Hansen Assets for EUR150 Million	Dec. 12	DJ
European Commission clears Novozymes, Chr. Hansen merger	Dec. 12	RE
Kerry Group plc agreed to acquire Lactase enzyme business from Chr. Hansen Holding A/S and Novozymes A/S (CPSE:NZYM B) for ?150 million.	Dec. 11	CI
Simon Barnard: A long-term vision at Smithson	Dec. 07
EU regulators likely to clear Novozymes, Chr. Hansen deal, sources say	Dec. 06	RE
EU ANTITRUST REGULATORS LIKELY TO APPROVE NOVOZYMES, C…	Dec. 06	RE
EU Competition Watchdog Extends Novozymes, Chr. Hansen Merger Decision	Nov. 21	MT
EU extends decision date on Novoyzmes, Chr. Hansen deal to Dec. 12	Nov. 21	RE
Novozymes, Chr. Hansen Propose Remedy to Secure EU Approval for Merger	Nov. 20	MT

Chr. Hansen Holding A/S specializes in the development, production and marketing of biotechnological ingredients for the food processing, animal feed and health industries. Net sales (excluding activities being sold) break down by family of products as follows: - cultivations and enzymes (62.6%); - medical and nutritional ingredients (37.4%): used in the manufacturing of dietary supplements, OTC drugs, baby products and animal feed. Net sales are distributed geographically as follows: Denmark (0.8%), Europe/Middle East/Africa (36.4%), the United States (30.3%), North America (2.4%), Asia/Pacific (18.7%) and Latin America (11.4%).

Sector

Food Processing

Calendar

2024-05-06 - Q1 2024 Sales and Revenue Release - Trading Update

More about the company

Sector Food Ingredients

	1st Jan change	Capi.
FOSHAN HAITIAN FLAVOURING AND FOOD COMPANY LTD.	+0.13%	29.17B
INTERNATIONAL FLAVORS & FRAGRANCES INC.	+4.84%	21.67B
KIKKOMAN CORPORATION	+12.43%	11.81B
LANCASTER COLONY CORPORATION	+11.54%	5.11B
MEIHUA HOLDINGS GROUP CO.,LTD	+11.73%	4.23B
ANGEL YEAST CO., LTD	-17.57%	3.43B
TATE & LYLE PLC	-1.82%	3.17B
JONJEE HI-TECH INDUSTRIAL AND COMMERCIAL HOLDING CO.,LTD	-3.70%	2.88B
KEWPIE CORPORATION	+25.46%	2.8B

Food Ingredients

Christian Hansen

Equities

CHR

DK0060227585

Food Processing

Chr. Hansen Holding A/S Provides Earnings Guidance for the Year 2022

Latest news about Christian Hansen

Chart Christian Hansen

Company Profile

Sector Food Ingredients